The Effect of Neoadjuvant Chemotherapy on Histologic Grade, Hormone Receptor Status, and Her2/neu Status in Breast Carcinoma
- 1 March 2008
- journal article
- research article
- Published by Hindawi Limited in The Breast Journal
- Vol. 14 (2) , 141-146
- https://doi.org/10.1111/j.1524-4741.2007.00544.x
Abstract
The use of neoadjuvant chemotherapy prior to surgical resection for breast cancer is no longer restricted to patients with locally advanced disease. As preoperative treatment becomes more common, the question arises whether or not such therapy changes important tumor characteristics. The objective of our study is to compare histological grade, hormone receptor status, and HER2/neu expression pre- and post-therapy patients receiving preoperative neo-adjuvant chemotherapy. Forty patients status post-neoadjuvant treatment who had available archived pathologic material pre- and post-therapy were identified. Glass slides were reviewed retrospectively, and tumor grade, hormone receptor status, and HER2/neu expression were compared between the pre- and post-therapy specimens. No significant differences were noted between the pre- and post-specimens for two of the three parameters comprising the modified Bloom-Richardson grade, including degree of tubule formation (p = 0.062) and nuclear pleomorphism (p = 0.086). For mitotic activity, a decrease in score was observed between pre- and post-therapy specimens which was statistically significant (p = 0.021). However, there was no significant difference in the overall modified Bloom-Richardson grade (p = 0.118). Information was available regarding hormone receptor and HER2/neu status in 26 patients (65%). There was no significant difference between pre- and post-treatment specimens for hormone receptor status. However, there were more patients with HER2/neu overexpression after receiving neoadjuvant therapy (p = 0.027). Neoadjuvant therapy resulted in a significant decrease in mitotic count and an increase in the proportion of patients with HER2/neu overexpression. No significant changes were noted for the degree of tubule formation, nuclear pleomorphism, overall Bloom-Richardson score, and hormone receptor status. However, small sample size may be a limitation of these results.Keywords
This publication has 18 references indexed in Scilit:
- Do the histologic features and results of breast cancer biomarker studies differ between core biopsy and surgical excision specimens?The Breast, 2006
- Preoperative (neoadjuvant) systemic treatment of breast cancerThe Breast, 2005
- Biomarker Changes During Neoadjuvant Anastrozole, Tamoxifen, or the Combination: Influence of Hormonal Status and HER-2 in Breast Cancer—A Study from the IMPACT TrialistsJournal of Clinical Oncology, 2005
- Influence of Neoadjuvant Therapy with Epirubicin and Docetaxel on the Expression of HER2/neu in Patients with Breast CancerBreast Cancer Research and Treatment, 2003
- Mode of action of docetaxel – a basis for combination with novel anticancer agentsCancer Treatment Reviews, 2003
- Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy.Endocrine-Related Cancer, 2003
- HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic processCancer, 2002
- Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: A pilot studyBreast Cancer Research and Treatment, 1999
- Proliferating Fraction During Neoadjuvant Chemotherapy of Primary Breast Cancer in Relation to Objective Local Response and Relapse-free SurvivalActa Oncologica, 1999
- Morphologic Effects of Neoadjuvant Chemotherapy in Locally Advanced Breast CancerPathology - Research and Practice, 1997